UY39740A - Formas cristalinas de un inhibidor de tirosina quinasa de bruton - Google Patents
Formas cristalinas de un inhibidor de tirosina quinasa de brutonInfo
- Publication number
- UY39740A UY39740A UY0001039740A UY39740A UY39740A UY 39740 A UY39740 A UY 39740A UY 0001039740 A UY0001039740 A UY 0001039740A UY 39740 A UY39740 A UY 39740A UY 39740 A UY39740 A UY 39740A
- Authority
- UY
- Uruguay
- Prior art keywords
- bruton
- tyrosine kinase
- crystalline forms
- inhibitor
- kinase inhibitor
- Prior art date
Links
- 229940125814 BTK kinase inhibitor Drugs 0.000 title abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 2
- 229940124291 BTK inhibitor Drugs 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- -1 crystalline forms Chemical compound 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
- A61J1/035—Blister-type containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D75/00—Packages comprising articles or materials partially or wholly enclosed in strips, sheets, blanks, tubes, or webs of flexible sheet material, e.g. in folded wrappers
- B65D75/28—Articles or materials wholly enclosed in composite wrappers, i.e. wrappers formed by associating or interconnecting two or more sheets or blanks
- B65D75/30—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding
- B65D75/32—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
- B65D75/36—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet or blank being recessed and the other formed of relatively stiff flat sheet material, e.g. blister packages, the recess or recesses being preformed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
Se describe aquí al inhibidor de tirosina quinasa (Btk) de Bruton 1-((R)-3-(4-amino-3-(4-fenoxifenil)-1H-pirazolo[3,4-d] pirimidin-1-il)piperidin-1-il)prop-2-en-1-ona, incluyendo las formas cristalinas, solvatos y sus sales aceptables en el campo farmacéutico. Se describe también composiciones farmacéuticas que incluyen al inhibidor Btk, así como métodos para usar a dicho inhibidor solo o en combinación con otros agentes terapéuticos, para el tratamiento de enfermedades o condiciones autoinmunes, enfermedades o condiciones heteroinmunes, cáncer, incluyendo linfoma, así como enfermedades o condiciones inflamatorias.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261655381P | 2012-06-04 | 2012-06-04 | |
UY0001034848A UY34848A (es) | 2012-06-04 | 2013-06-04 | Formas cristalinas de un inhibidor de tirosina quinasa de bruton |
Publications (1)
Publication Number | Publication Date |
---|---|
UY39740A true UY39740A (es) | 2022-06-30 |
Family
ID=49712527
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001039740A UY39740A (es) | 2012-06-04 | 2013-06-04 | Formas cristalinas de un inhibidor de tirosina quinasa de bruton |
UY0001034848A UY34848A (es) | 2012-06-04 | 2013-06-04 | Formas cristalinas de un inhibidor de tirosina quinasa de bruton |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001034848A UY34848A (es) | 2012-06-04 | 2013-06-04 | Formas cristalinas de un inhibidor de tirosina quinasa de bruton |
Country Status (32)
Country | Link |
---|---|
US (25) | US9540382B2 (es) |
EP (1) | EP2854859A4 (es) |
JP (8) | JP6236071B2 (es) |
KR (7) | KR20190040370A (es) |
CN (2) | CN104736178A (es) |
AR (2) | AR092844A1 (es) |
AU (6) | AU2013271918C1 (es) |
BR (1) | BR112014030424A8 (es) |
CA (4) | CA3218491A1 (es) |
CL (3) | CL2014003306A1 (es) |
CO (1) | CO7240408A2 (es) |
CR (1) | CR20140558A (es) |
DO (3) | DOP2014000274A (es) |
EA (1) | EA201492082A1 (es) |
EC (2) | ECSP14033163A (es) |
GT (1) | GT201400281A (es) |
HK (1) | HK1208803A1 (es) |
IL (3) | IL235894B (es) |
JO (2) | JO3754B1 (es) |
MA (2) | MA41654B2 (es) |
MX (2) | MX348290B (es) |
MY (2) | MY187999A (es) |
NZ (4) | NZ702548A (es) |
PE (2) | PE20150174A1 (es) |
PH (2) | PH12014502681A1 (es) |
SG (2) | SG10202101389TA (es) |
TN (1) | TN2014000492A1 (es) |
TW (3) | TWI662963B (es) |
UA (2) | UA126959C2 (es) |
UY (2) | UY39740A (es) |
WO (1) | WO2013184572A1 (es) |
ZA (3) | ZA202105174B (es) |
Families Citing this family (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2081435B1 (en) | 2006-09-22 | 2016-05-04 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
US20120101113A1 (en) | 2007-03-28 | 2012-04-26 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
EP3311818A3 (en) | 2008-07-16 | 2018-07-18 | Pharmacyclics, LLC | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
US8491927B2 (en) * | 2009-12-02 | 2013-07-23 | Nimble Epitech, Llc | Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor |
WO2011153514A2 (en) | 2010-06-03 | 2011-12-08 | Pharmacyclics, Inc. | The use of inhibitors of bruton's tyrosine kinase (btk) |
BR112013017722A2 (pt) | 2011-01-11 | 2016-07-12 | Glaxosmithkline Llc | combinação |
WO2013010136A2 (en) | 2011-07-13 | 2013-01-17 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
ES2671748T3 (es) | 2011-07-21 | 2018-06-08 | Tolero Pharmaceuticals, Inc. | Inhibidores heterocíclicos de proteína quinasas |
PT2788343T (pt) | 2011-12-11 | 2018-06-01 | Viamet Pharmaceuticals Nc Inc | Compostos inibidores de metaloenzimas |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
NZ702548A (en) * | 2012-06-04 | 2015-11-27 | Pharmacyclics Llc | Crystalline forms of a bruton’s tyrosine kinase inhibitor |
JP6575950B2 (ja) | 2012-07-24 | 2019-09-18 | ファーマサイクリックス エルエルシー | Bruton型チロシンキナーゼ(Btk)阻害剤に対する耐性を伴う変異 |
CN111329989A (zh) | 2012-11-02 | 2020-06-26 | 药品循环有限责任公司 | Tec家族激酶抑制剂辅助疗法 |
MX2015006168A (es) | 2012-11-15 | 2015-08-10 | Pharmacyclics Inc | Compuestos de pirrolopirimidina como inhibidores de quinasas. |
US10202356B2 (en) | 2013-03-14 | 2019-02-12 | Tolero Pharmaceuticals, Inc. | JAK2 and ALK2 inhibitors and methods for their use |
CN105492011A (zh) | 2013-04-08 | 2016-04-13 | 丹尼斯·M·布朗 | 不理想给药化学化合物的治疗增效 |
CA2920534A1 (en) | 2013-08-12 | 2015-02-19 | Pharmacyclics Llc | Methods for the treatment of her2 amplified cancer |
JP2016528297A (ja) * | 2013-08-22 | 2016-09-15 | ヴァンダ ファーマシューティカルズ インコーポレイテッド | 癌治療 |
PE20160560A1 (es) | 2013-09-30 | 2016-06-09 | Pharmacyclics Llc | DERIVADOS DE PIRAZOLO[3,4-d]PIRIMIDIN COMO INHIBIDORES IRREVERSIBLES DE LA TIROSINA CINASA DE BRUTON (BTK) |
US20160250208A1 (en) * | 2013-10-11 | 2016-09-01 | University Of Massachusetts | Treating organ-specific t cell mediated autoimmune diseases |
US9795604B2 (en) | 2013-10-25 | 2017-10-24 | Pharmacyclics Llc | Methods of treating and preventing graft versus host disease |
WO2015071432A1 (en) * | 2013-11-14 | 2015-05-21 | Sandoz Ag | Pharmaceutical compositions of ibrutinib |
CN103694241A (zh) | 2013-11-27 | 2014-04-02 | 苏州晶云药物科技有限公司 | Pci-32765的新晶型a及其制备方法 |
US10272083B2 (en) * | 2014-01-21 | 2019-04-30 | Acerta Pharma B.V. | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
CN105949198A (zh) * | 2014-01-29 | 2016-09-21 | 苏州晶云药物科技有限公司 | 依鲁替尼的新晶型及其制备方法 |
CN106456642A (zh) * | 2014-03-12 | 2017-02-22 | 诺华股份有限公司 | 含btk抑制剂与akt抑制剂的组合 |
US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
MX2016012419A (es) | 2014-03-27 | 2016-11-30 | Perrigo Api Ltd | Formas solidas de ibrutinib y procesos para la produccion de las mismas. |
CN105085529A (zh) * | 2014-05-15 | 2015-11-25 | 广东东阳光药业有限公司 | 依鲁替尼新晶型及其制备方法 |
US20160008366A1 (en) * | 2014-07-14 | 2016-01-14 | Pharmacyclics Llc | Btk inhibitors for the treatment of cns malignancies |
US9533991B2 (en) | 2014-08-01 | 2017-01-03 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
CA2955744A1 (en) * | 2014-08-01 | 2016-02-04 | Pharmacyclics Llc | Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor |
JP2017523206A (ja) * | 2014-08-07 | 2017-08-17 | ファーマサイクリックス エルエルシー | ブルトン型チロシンキナーゼ阻害剤の新規製剤 |
US9730938B2 (en) * | 2014-08-08 | 2017-08-15 | Pharmacyclics Llc | Bruton's tyrosine kinase inhibitor combinations and uses thereof |
WO2016025720A1 (en) | 2014-08-14 | 2016-02-18 | Assia Chemical Industries Ltd. | Solid state forms of ibrutinib |
WO2016050422A1 (en) * | 2014-10-01 | 2016-04-07 | Ratiopharm Gmbh | Acid addition salt of ibrutinib |
WO2016079216A1 (en) | 2014-11-20 | 2016-05-26 | Sandoz Ag | Physical forms of ibrutinib, a bruton's kinase inhibitor |
CA2974335C (en) * | 2015-01-30 | 2019-04-09 | Taiho Pharmaceutical Co., Ltd. | Novel salt of fused pyrimidine compound and crystal thereof |
CZ201584A3 (cs) | 2015-02-09 | 2016-08-17 | Zentiva, K.S. | Sůl Ibrutinib sulfátu |
BR122023020985A2 (pt) | 2015-03-03 | 2023-12-26 | Pharmacyclics Llc | Formulação de comprimido sólido de um inibidor de tirosina quinase de bruton |
RU2017133663A (ru) * | 2015-03-03 | 2019-04-03 | Др. Редди'С Лабораторис Лимитед | П0лиморфы ибрутиниба |
EP3272753B1 (en) * | 2015-03-20 | 2020-03-04 | Crystal Pharmatech Co., Ltd. | Preparation method of pci-32765 crystal form a |
MA41827A (fr) * | 2015-03-27 | 2018-01-30 | Pharmacyclics Llc | Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton |
MA41828A (fr) * | 2015-03-27 | 2018-01-30 | Pharmacyclics Llc | Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton |
CN107873029B (zh) * | 2015-04-02 | 2020-09-01 | 拉蒂奥法姆有限责任公司 | 依鲁替尼与羧酸的共晶体 |
MA41901A (fr) * | 2015-04-06 | 2021-04-14 | Janssen Pharmaceutica Nv | Compositions contenant de l'ibrutinib |
CN106153797B (zh) * | 2015-04-20 | 2017-08-29 | 北京睿创康泰医药研究院有限公司 | 一种依鲁替尼及依鲁替尼制剂有关物质分析方法 |
CN106153798B (zh) * | 2015-04-22 | 2017-08-29 | 北京睿创康泰医药研究院有限公司 | 一种用于分析依鲁替尼及依鲁替尼制剂有关物质的hplc方法以及这些杂质做参比标准的用途 |
WO2016207172A1 (en) * | 2015-06-26 | 2016-12-29 | Sandoz Gmbh | Preparation of pure amorphous ibrutinib |
CZ2015442A3 (cs) * | 2015-06-26 | 2017-01-04 | Zentiva, K.S. | Ibrutinib hemisulfát |
WO2017011314A1 (en) * | 2015-07-10 | 2017-01-19 | Paharmacyclics Llc | Btk and hdac combinations |
US11001585B2 (en) | 2015-08-19 | 2021-05-11 | Sun Pharmaceutical Industries Limited | Crystalline forms of ibrutinib |
US10464921B2 (en) | 2015-09-18 | 2019-11-05 | Mycovia Pharmaceuticals, Inc. | Antifungal compound process |
US9834561B2 (en) * | 2015-10-28 | 2017-12-05 | Scinopharm Taiwan, Ltd. | Process for preparing ibrutinib and its intermediates |
ITUB20155616A1 (it) * | 2015-11-16 | 2017-05-16 | Laboratorio Chimico Int S P A | Procedimento per la preparazione della forma amorfa dell?ibrutinib e nuova forma cristallina. |
CN105294696A (zh) * | 2015-11-19 | 2016-02-03 | 上海创诺医药集团有限公司 | 依鲁替尼新晶型及其制备方法 |
MA43377A (fr) | 2015-12-04 | 2021-05-19 | Hutchinson Fred Cancer Res | Méthodes et compositions liées à la toxicité associée à la thérapie cellulaire |
CN105622614B (zh) * | 2015-12-18 | 2021-02-26 | 重庆医药工业研究院有限责任公司 | 一种依鲁替尼无定型物及其制备方法 |
CN106905320A (zh) * | 2015-12-23 | 2017-06-30 | 杭州容立医药科技有限公司 | 一种适合药用的依鲁替尼及其制剂 |
AU2017208472B2 (en) * | 2016-01-19 | 2022-09-01 | Janssen Pharmaceutica Nv | Formulations/compositions comprising a BTK inhibitor |
CN114681462A (zh) * | 2016-01-19 | 2022-07-01 | 詹森药业有限公司 | 包含btk抑制剂的配制品/组合物 |
CN106995445B (zh) * | 2016-01-22 | 2021-08-03 | 山东新时代药业有限公司 | 一种布鲁顿酪氨酸激酶抑制剂晶型及其制备方法 |
KR20180103089A (ko) * | 2016-01-27 | 2018-09-18 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 퀴놀린 유도체 또는 그의 염을 포함하는 약학적 조성물 |
WO2017134684A2 (en) | 2016-02-01 | 2017-08-10 | Natco Pharma Limited | An improved process for the preparation of ibrutinib |
US10435409B2 (en) | 2016-02-04 | 2019-10-08 | Shilpa Medicare Limited | Process for the preparation of ibrutinib |
GB2558514A (en) * | 2016-02-09 | 2018-07-18 | Azad Pharmaceutical Ingredients Ag | Process for the synthesis of stable amorphous ibrutinib |
CN105646498A (zh) * | 2016-03-01 | 2016-06-08 | 孙霖 | 依鲁替尼晶型f及制备方法 |
CN107286163A (zh) * | 2016-03-30 | 2017-10-24 | 上海星泰医药科技有限公司 | 一种依鲁替尼的新晶型及其制备方法 |
CZ2016196A3 (cs) | 2016-04-06 | 2017-10-18 | Zentiva, K.S. | Pevné formy Ibrutinibu |
CZ2016276A3 (cs) | 2016-05-11 | 2017-11-22 | Zentiva, K.S. | Pevné formy volné báze ibrutinibu |
US20180228749A1 (en) * | 2016-06-28 | 2018-08-16 | Mehmet Nevzat Pisak | Surfactants and compositions for treatment of viral skin conditions |
CN106117214A (zh) * | 2016-06-29 | 2016-11-16 | 上海创诺医药集团有限公司 | 依鲁替尼新晶型及其制备方法 |
IL263815B (en) | 2016-06-29 | 2022-07-01 | Principia Biopharma Inc | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(Oxtan-3-yl)piperazin-1-yl)pent-2-ananitrile |
WO2018085731A2 (en) | 2016-11-03 | 2018-05-11 | Juno Therapeutics, Inc. | Combination therapy of a t cell therapy and a btk inhibitor |
US10183024B2 (en) | 2016-12-02 | 2019-01-22 | Apotex Inc. | Crystalline forms of ibrutinib |
GB201703876D0 (en) | 2017-03-10 | 2017-04-26 | Berlin-Chemie Ag | Pharmaceutical combinations |
CN108653231A (zh) * | 2017-04-01 | 2018-10-16 | 北京赛林泰医药技术有限公司 | 含有布鲁顿酪氨酸激酶抑制剂的组合物及其制备方法 |
MA48781A (fr) | 2017-06-02 | 2020-04-08 | Juno Therapeutics Inc | Articles de fabrication et procédés liés à la toxicité associée à la thérapie cellulaire |
WO2018223101A1 (en) | 2017-06-02 | 2018-12-06 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
JP2020526194A (ja) | 2017-06-29 | 2020-08-31 | ジュノー セラピューティクス インコーポレイテッド | 免疫療法薬と関連する毒性を評価するためのマウスモデル |
JP7190452B2 (ja) | 2017-07-04 | 2022-12-15 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | 医薬組成物及びその製造方法 |
MA50057A (fr) | 2017-09-01 | 2020-07-08 | Juno Therapeutics Inc | Expression génique et évaluation d'un risque de développement d'une toxicité suite à une thérapie cellulaire |
EP3684367A1 (en) | 2017-09-19 | 2020-07-29 | Cipla Limited | Compositions comprising ibrutinib and an alkaloid having enhanced bioavailability |
WO2019070698A1 (en) | 2017-10-02 | 2019-04-11 | Johnson Matthey Public Limited Company | NEW FORMS OF IBRUTINIB |
WO2019089848A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
CZ2017787A3 (cs) | 2017-12-08 | 2019-06-19 | Zentiva, K.S. | Farmaceutické kompozice obsahující ibrutinib |
CA3089537A1 (en) | 2018-01-20 | 2019-07-25 | Natco Pharma Limited | Pharmaceutical compositions comprising ibrutinib |
MX2020010437A (es) | 2018-04-05 | 2021-01-29 | Sumitomo Pharma Oncology Inc | Inhibidores de axl cinasa y uso de los mismos. |
WO2019195827A1 (en) * | 2018-04-06 | 2019-10-10 | Johnson Matthey Public Limited Company | Novel form of ibrutinib |
US20210113562A1 (en) | 2018-04-13 | 2021-04-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer |
WO2019211870A1 (en) | 2018-05-02 | 2019-11-07 | Cipla Limited | Polymorphic forms of ibrutinib |
CA3098497A1 (en) | 2018-05-03 | 2019-11-07 | Juno Therapeutics, Inc. | Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor |
EP3575300A1 (en) | 2018-05-31 | 2019-12-04 | Apotex Inc. | Novel crystalline forms of ibrutinib |
RU2711106C2 (ru) * | 2018-06-06 | 2020-01-15 | Общество с ограниченной ответственностью "АКСЕЛЬФАРМ" | Кристаллическая μ-модификация 1-[(3R)-3-[4-амино-3-(4-фенокси-фенил)-1Н-пиразоло[3,4-d]пиримидин-1-ил]-1-пиперидил]-2-пропенил-1-она, способ её получения и фармацевтическая композиция на её основе |
EA202190045A1 (ru) | 2018-06-15 | 2021-03-17 | Янссен Фармацевтика Нв | Составы/композиции, содержащие ибрутиниб |
JP2021527685A (ja) | 2018-06-19 | 2021-10-14 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | 1−(4−{[6−アミノ−5−(4−フェノキシ−フェニル)−ピリミジン−4−イルアミノ]−メチル}−4−フルオロ−ピペリジン−1−イル)−プロペノンの新規な結晶形態、その塩形態、および得るためのプロセス |
CN108727387B (zh) * | 2018-07-25 | 2021-03-16 | 天津大学 | 依鲁替尼乙酸异丙酯溶剂化合物及其制备方法 |
CA3103995A1 (en) | 2018-07-26 | 2020-01-30 | Sumitomo Dainippon Pharma Oncology, Inc. | Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same |
CN110804058B (zh) * | 2018-08-06 | 2022-11-11 | 鲁南制药集团股份有限公司 | 一种伊布替尼新晶型及其制备方法 |
CN111138436A (zh) * | 2018-11-04 | 2020-05-12 | 鲁南制药集团股份有限公司 | 伊布替尼晶型a单晶及其制备方法 |
JP2022513685A (ja) | 2018-11-30 | 2022-02-09 | ジュノー セラピューティクス インコーポレイテッド | 養子細胞療法を用いた処置のための方法 |
MX2021006244A (es) | 2018-11-30 | 2021-09-10 | Juno Therapeutics Inc | Metodos de dosificacion y tratamiento de canceres de celulas b en terapia celular adoptiva. |
KR20210100677A (ko) * | 2018-12-06 | 2021-08-17 | 아쓰로시 테라퓨틱스, 인크. | 통풍 또는 고뇨산혈증의 치료 또는 예방을 위한 화합물의 결정형 |
EP3669867A1 (en) | 2018-12-21 | 2020-06-24 | Synthon B.V. | Pharmaceutical composition comprising ibrutinib |
US10688050B1 (en) | 2018-12-21 | 2020-06-23 | Synthon B.V. | Pharmaceutical composition comprising ibrutinib |
EP3924351A4 (en) | 2019-02-12 | 2022-12-21 | Sumitomo Pharma Oncology, Inc. | FORMULATIONS COMPRISING HETEROCYCLIC PROTEIN KINASE INHIBITORS |
JP2023504737A (ja) | 2019-12-06 | 2023-02-06 | ジュノー セラピューティクス インコーポレイテッド | B細胞性悪性疾患を処置するための細胞療法と関連する毒性および奏効に関係する方法 |
CN113135917A (zh) * | 2020-01-16 | 2021-07-20 | 北京赛思源生物医药技术有限公司 | 一种依鲁替尼的无定型物及其药用组合物 |
CN113214261A (zh) * | 2020-01-21 | 2021-08-06 | 尚科生物医药(上海)有限公司 | 一种依鲁替尼晶型a的纯化方法 |
EP4203923A1 (en) | 2020-08-28 | 2023-07-05 | Synthon B.V. | Pharmaceutical composition comprising ibrutinib |
EP4281454A1 (en) | 2021-01-21 | 2023-11-29 | Synthon B.V. | Process for making ibrutinib |
WO2022260667A1 (en) | 2021-06-10 | 2022-12-15 | Hikma Pharmaceuticals Usa Inc. | Oral dosage forms of ibrutinib |
US11433072B1 (en) | 2021-06-10 | 2022-09-06 | Hikma Pharmaceuticals USA, Inc. | Oral dosage forms of ibrutinib |
WO2023014817A1 (en) | 2021-08-03 | 2023-02-09 | Syros Pharmaceuticals, Inc. | Compositions and methods for treating lymphomas with a cdk7 inhibitor in combination with a btk inhibitor |
WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
WO2023242384A1 (en) | 2022-06-17 | 2023-12-21 | Krka, D.D., Novo Mesto | Crystalline form of ibrutinib |
Family Cites Families (197)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1006596A (en) | 1909-05-20 | 1911-10-24 | Kansas City Feed Company Ltd | Alfalfa-mill. |
US1008594A (en) | 1910-12-17 | 1911-11-14 | Arthur Graham France | Advertising device. |
US1010536A (en) | 1911-05-01 | 1911-12-05 | John B Turbeville | Cook-stove. |
US1010654A (en) | 1911-06-20 | 1911-12-05 | Albert F Madden | Cyclometer. |
JPS5841998B2 (ja) | 1980-07-28 | 1983-09-16 | 株式会社日立製作所 | 核燃料掴み装置 |
US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
DE3303707A1 (de) | 1983-02-04 | 1984-08-09 | Dynamit Nobel Ag, 5210 Troisdorf | Verfahren zur spaltung von organosiloxanen und dessen produkte und anwendungen |
US4624848A (en) | 1984-05-10 | 1986-11-25 | Ciba-Geigy Corporation | Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use |
US4968509A (en) | 1987-07-27 | 1990-11-06 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
JPH01167840A (ja) | 1987-12-24 | 1989-07-03 | Konica Corp | 新規な写真用シアンカプラー |
IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Hydrogel-operated release devices |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
EP0580860B2 (en) | 1991-04-16 | 2004-12-15 | Nippon Shinyaku Company, Limited | Method of manufacturing solid dispersion |
ES2149781T3 (es) | 1991-11-22 | 2000-11-16 | Procter & Gamble Pharma | Composiciones de risedronato de liberacion retardada. |
US5461140A (en) | 1992-04-30 | 1995-10-24 | Pharmaceutical Delivery Systems | Bioerodible polymers for solid controlled release pharmaceutical compositions |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
DE69332291T2 (de) | 1992-10-16 | 2003-07-31 | Nippon Shinyaku Co Ltd | Verfahren zur herstellung von wachsmatrizes |
GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
US6326469B1 (en) | 1994-04-22 | 2001-12-04 | Sugen, Inc. | Megakaryocytic protein tyrosine kinases |
CA2220451A1 (en) | 1995-05-17 | 1996-11-21 | Cedars-Sinai Medical Center | Methods and compositions for improving digestion and absorption in the small intestine |
US5593997A (en) | 1995-05-23 | 1997-01-14 | Pfizer Inc. | 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors |
US5994348A (en) | 1995-06-07 | 1999-11-30 | Sanofi | Pharmaceutical compositions containing irbesartan |
CH690773A5 (de) | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo(2,3-d)pyrimide und ihre Verwendung. |
AU3176297A (en) | 1996-06-25 | 1998-01-14 | Novartis Ag | Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof |
CA2283961A1 (en) | 1997-03-19 | 1998-09-24 | Basf Aktiengesellschaft | Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors |
DK0901786T3 (da) | 1997-08-11 | 2007-10-08 | Pfizer Prod Inc | Faste farmaceutiske dispersioner med foröget biotilgængelighed |
DE69808670T2 (de) | 1997-12-31 | 2003-07-03 | Choongwae Pharma Corp | Herstellungsverfahren und zusammensetzung einer oralen zubereitung von itraconazol |
JP2002512216A (ja) | 1998-04-17 | 2002-04-23 | パーカー ヒューズ インスティテュート | Btkインヒビターならびにその同定方法および使用方法 |
US6303652B1 (en) | 1998-08-21 | 2001-10-16 | Hughes Institute | BTK inhibitors and methods for their identification and use |
US7122207B2 (en) | 1998-05-22 | 2006-10-17 | Bristol-Myers Squibb Company | High drug load acid labile pharmaceutical composition |
US20050287596A9 (en) | 1998-06-26 | 2005-12-29 | Braisted Andrew C | Novel ligands and libraries of ligands |
US6335155B1 (en) | 1998-06-26 | 2002-01-01 | Sunesis Pharmaceuticals, Inc. | Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules |
US6998233B2 (en) | 1998-06-26 | 2006-02-14 | Sunesis Pharmaceuticals, Inc. | Methods for ligand discovery |
UA74141C2 (uk) | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти) |
ES2307482T3 (es) | 1999-02-10 | 2008-12-01 | Pfizer Products Inc. | Dispersiones farmaceuticas solidas. |
US6306897B1 (en) | 1999-03-19 | 2001-10-23 | Parker Hughes Institute | Calanolides for inhibiting BTK |
US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
IL148718A0 (en) | 1999-09-17 | 2002-09-12 | Abbott Gmbh & Co Kg | Pyrazolopyrimidines as therapeutic agents |
US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
EP1222187B1 (en) | 1999-10-06 | 2004-09-22 | Boehringer Ingelheim Pharmaceuticals Inc. | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
US6506769B2 (en) | 1999-10-06 | 2003-01-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
JP2003516351A (ja) | 1999-11-30 | 2003-05-13 | パーカー ヒューズ インスティテュート | コラーゲン誘導血小板凝集阻害剤 |
JP2003532632A (ja) | 1999-12-17 | 2003-11-05 | アライアッド・ファーマシューティカルズ・インコーポレーテッド | 新規の複素環 |
GB0005345D0 (en) | 2000-03-06 | 2000-04-26 | Mathilda & Terence Kennedy Ins | Methods of treating sepsis septic shock and inflammation |
GB0108903D0 (en) | 2000-10-05 | 2001-05-30 | Aventis Pharm Prod Inc | Novel crystalline forms of a factor Xa inhibitor |
AU2002236692A1 (en) | 2000-10-23 | 2002-05-21 | Bristol-Myers Squibb Company | Modulators of bruton's tyrosine kinase and bruton's tyrosine kinase, their identification and use |
JP2004514732A (ja) | 2000-12-06 | 2004-05-20 | ファルマシア・コーポレーション | 迅速に分散する医薬組成物 |
US6465014B1 (en) | 2001-03-21 | 2002-10-15 | Isp Investments Inc. | pH-dependent sustained release, drug-delivery composition |
MXPA03008560A (es) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
US8306897B2 (en) | 2001-05-04 | 2012-11-06 | Stockshield, Inc. | Method and system for insuring against investment loss |
US20030114467A1 (en) | 2001-06-21 | 2003-06-19 | Shakespeare William C. | Novel pyrazolo- and pyrrolo-pyrimidines and uses thereof |
EP1425577A4 (en) | 2001-08-10 | 2004-12-29 | Symyx Technologies Inc | APPARATUSES AND METHODS FOR PREPARING AND TESTING PRE-FORMULATIONS AND CORRESPONDING SYSTEMS |
CN1523991A (zh) | 2001-08-10 | 2004-08-25 | ��˹��ŵ�� | 单独的c-Src抑制剂或其与STI571的组合用于治疗白血病的用途 |
WO2003016338A1 (en) | 2001-08-15 | 2003-02-27 | Parker Hughes Institute | Crystal structure of the btk kinase domain |
JP4391237B2 (ja) | 2001-11-21 | 2009-12-24 | サネシス ファーマシューティカルズ, インコーポレイテッド | リガンド発見のための方法 |
US20050084905A1 (en) | 2002-03-21 | 2005-04-21 | Prescott John C. | Identification of kinase inhibitors |
GB2388594A (en) | 2002-05-16 | 2003-11-19 | Bayer Ag | Imidazo-triazine PDE 4 inhibitors |
WO2004014905A1 (en) | 2002-08-08 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted benzimidazole compounds |
GB0303910D0 (en) | 2003-02-20 | 2003-03-26 | Merck Sharp & Dohme | Therapeutic agents |
US7687506B2 (en) | 2003-04-11 | 2010-03-30 | The Regents Of The University Of California | Selective serine/threonine kinase inhibitors |
US20050008640A1 (en) | 2003-04-23 | 2005-01-13 | Wendy Waegell | Method of treating transplant rejection |
EP1473039A1 (en) | 2003-05-02 | 2004-11-03 | Centre National De La Recherche Scientifique (Cnrs) | Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis |
US7405295B2 (en) | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
WO2005005429A1 (en) | 2003-06-30 | 2005-01-20 | Cellular Genomics, Inc. | Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds |
EP1664762A4 (en) | 2003-09-03 | 2008-08-13 | Us Gov Health & Human Serv | METHODS OF IDENTIFICATION, DIAGNOSIS AND PREDICTION FOR LYMPHOMES SURVIVAL |
US8131475B2 (en) | 2003-09-03 | 2012-03-06 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Methods for identifying, diagnosing, and predicting survival of lymphomas |
CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
JP4916883B2 (ja) | 2003-10-15 | 2012-04-18 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | イミダゾピラジンチロシンキナーゼ阻害剤 |
US20070196395A1 (en) | 2003-12-12 | 2007-08-23 | Mackerell Alexander | Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain |
US20050153990A1 (en) | 2003-12-22 | 2005-07-14 | Watkins William J. | Phosphonate substituted kinase inhibitors |
BRPI0418031A (pt) | 2003-12-22 | 2007-04-17 | Gilead Sciences Inc | inibidores de quinase fosfonato-substituìdos |
WO2005070393A2 (en) | 2004-01-08 | 2005-08-04 | Wyeth | Directly compressible pharmaceutical composition of the rapamycin ester cci-779 |
US7855214B2 (en) | 2004-01-26 | 2010-12-21 | Vertex Pharmaceuticals Incorporated | Fused cyclic systems useful as inhibitors of TEC family protein kinases |
CA2553724A1 (en) | 2004-02-03 | 2005-08-18 | Abbott Laboratories | Aminobenzoxazoles as therapeutic agents |
ITMI20041314A1 (it) | 2004-06-30 | 2004-09-30 | Nuvera Fuel Cells Europ Srl | Dispositivo di raffreddamento per celle a combustibili a membrana |
AR053090A1 (es) | 2004-07-20 | 2007-04-25 | Osi Pharm Inc | Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos |
EP1794137A4 (en) | 2004-09-27 | 2009-12-02 | Kosan Biosciences Inc | SPECIFIC KINASE INHIBITORS |
EP1802602A1 (en) | 2004-09-28 | 2007-07-04 | Janssen Pharmaceutica N.V. | Substituted dipiperdine ccr2 antagonists |
EP1812442A2 (en) | 2004-11-10 | 2007-08-01 | CGI Pharmaceuticals, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines useful as modulators of kinase activity |
GB0425035D0 (en) | 2004-11-12 | 2004-12-15 | Novartis Ag | Organic compounds |
SG160364A1 (en) | 2005-03-07 | 2010-04-29 | Bayer Schering Pharma Ag | Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer |
BRPI0608252A2 (pt) | 2005-03-10 | 2010-04-06 | Cgi Pharmaceuticals Inc | entidades quìmicas, composições farmacêuticas compreendendo as mesmas, métodos utilizando as referidas entidades quìmicas e uso das referidas entidades quìmicas |
EP1891066B1 (en) | 2005-05-13 | 2010-12-22 | Irm, Llc | Compounds and compositions as protein kinase inhibitors |
EP2266974A1 (en) | 2005-05-23 | 2010-12-29 | Novartis AG | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-Quinolin-2-one lactic acid salts |
CN102603581B (zh) | 2005-06-22 | 2015-06-24 | 普莱希科公司 | 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物 |
AU2006279794B2 (en) | 2005-08-12 | 2011-04-07 | Synta Pharmaceuticals Corp. | Pyrazole compounds that modulate HSP90 activity |
US20070065449A1 (en) | 2005-09-16 | 2007-03-22 | Claire Verschraegen | Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab) |
WO2007058832A2 (en) | 2005-11-12 | 2007-05-24 | Boehringer Ingelheim International Gmbh | Pyrrolo (2, 3-b) pyridine derivatives useful as tec kinase inhibitors |
MX2008008642A (es) | 2006-01-13 | 2008-09-12 | Pharmacyclics Inc | Inhibidores de las tirosina cinasas y usos de los mismos. |
WO2007089911A2 (en) | 2006-01-30 | 2007-08-09 | The Scripps Research Institute | Methods for detection of circulating tumor cells and methods of diagnosis of cancer in a mammalian subject |
TW200812611A (en) | 2006-03-20 | 2008-03-16 | Vertex Pharma | Pharmaceutical compositions |
CA2647391C (en) | 2006-04-04 | 2015-12-29 | The Regents Of The University Of California | Kinase antagonists |
CA2858520A1 (en) | 2006-05-18 | 2007-11-29 | Pharmacyclics Inc. | Intracellular kinase inhibitors |
DE102006026583A1 (de) | 2006-06-07 | 2007-12-13 | Bayer Healthcare Aktiengesellschaft | Aryl-substituierte hetero-bicyclische Verbindungen und ihre Verwendung |
EP2081435B1 (en) | 2006-09-22 | 2016-05-04 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
CA2668286C (en) | 2006-11-03 | 2014-09-16 | Pharmacyclics, Inc. | Bruton's tyrosine kinase activity probe and method of using |
FI20080352A0 (fi) | 2008-05-09 | 2008-05-09 | Atacama Labs Oy | Prosessi korkean lääkepitoisuuden tabletin valmistamiseksi |
EP2051702A1 (en) | 2007-01-22 | 2009-04-29 | Novavax, Inc. | Multi-phasic pharmaceutical formulations of poorly water-soluble drugs for reduced fed/fasted variability and improved oral bioavailability |
NL2000640C2 (nl) * | 2007-03-05 | 2008-09-08 | Stichting Wetsus Ct Of Excelle | Werkwijze en systeem voor het zuiveren van een vloeistof. |
US20120101113A1 (en) | 2007-03-28 | 2012-04-26 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
EP2560007A1 (en) | 2007-03-28 | 2013-02-20 | Pharmacyclics, Inc. | Identification of bruton's tyrosine kinase inhibitors |
US20120065201A1 (en) | 2007-03-28 | 2012-03-15 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
US20090010911A1 (en) | 2007-04-06 | 2009-01-08 | Iowa State University Research Foundation, Inc. | Methods and compositions for affecting cyclophilin a regulation of kinases in modulating cellular activities |
JP5462784B2 (ja) | 2007-04-27 | 2014-04-02 | パーデュー、ファーマ、リミテッド、パートナーシップ | Trpv1アンタゴニストとその使用 |
CA2693390C (en) | 2007-07-30 | 2017-01-17 | Ardea Biosciences, Inc. | Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same |
EP2214486A4 (en) | 2007-10-19 | 2011-03-09 | Avila Therapeutics Inc | HETEROARYL COMPOUNDS AND ITS USES |
CA2701275C (en) | 2007-10-23 | 2016-06-21 | F. Hoffmann-La Roche Ag | Kinase inhibitors |
US8426441B2 (en) | 2007-12-14 | 2013-04-23 | Roche Palo Alto Llc | Inhibitors of bruton's tyrosine kinase |
US20150152115A1 (en) | 2007-12-27 | 2015-06-04 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
EP2240022B1 (en) | 2008-01-09 | 2016-12-28 | Charleston Laboratories, Inc. | Bilayered tablets comprising oxycodone and promethazine |
WO2009124982A1 (en) | 2008-04-09 | 2009-10-15 | Lek Pharmaceuticals D.D. | Granulation of active pharmaceutical ingredients |
EP2291350A4 (en) | 2008-04-14 | 2012-09-19 | Ardea Biosciences Inc | COMPOSITIONS AND METHODS FOR THEIR MANUFACTURE AND USE |
EP2123626A1 (en) | 2008-05-21 | 2009-11-25 | Laboratorios del Dr. Esteve S.A. | Co-crystals of duloxetine and co-crystal formers for the treatment of pain |
BRPI0914682B8 (pt) | 2008-06-27 | 2021-05-25 | Avila Therapeutics Inc | compostos de heteroarila e composições compreendendo os referidos compostos |
EP3311818A3 (en) | 2008-07-16 | 2018-07-18 | Pharmacyclics, LLC | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
MX2011001005A (es) | 2008-07-29 | 2011-09-01 | Frontier Scient Inc | Uso de derivados de tetraquis (n-alquilpiridinio)-porfirina para eliminacion de microbios o prevencion del crecimiento. |
US8426428B2 (en) | 2008-12-05 | 2013-04-23 | Principia Biopharma, Inc. | EGFR kinase knockdown via electrophilically enhanced inhibitors |
WO2010068806A1 (en) | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer |
US8765754B2 (en) | 2009-04-29 | 2014-07-01 | Locus Pharmaceuticals, Inc. | Pyrrolotriazine compounds |
RU2012114902A (ru) | 2009-09-16 | 2013-10-27 | Авила Терапьютикс, Инк. | Конъюгаты и ингибиторы протеинкиназы |
US7741330B1 (en) | 2009-10-12 | 2010-06-22 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase |
MX2012013622A (es) | 2010-05-31 | 2013-02-01 | Ono Pharmaceutical Co | Derivado de purinona. |
US20120071497A1 (en) | 2010-06-03 | 2012-03-22 | Pharmacyclics, Inc. | Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase |
WO2011153514A2 (en) | 2010-06-03 | 2011-12-08 | Pharmacyclics, Inc. | The use of inhibitors of bruton's tyrosine kinase (btk) |
BR112012033253A2 (pt) | 2010-06-23 | 2016-11-22 | Hanmi Science Co Ltd | novos derivados de pirimidina fundidos para inibição da atividade de tirosina quinase |
KR20130099040A (ko) | 2010-08-10 | 2013-09-05 | 셀진 아빌로믹스 리서치, 인코포레이티드 | Btk 억제제의 베실레이트 염 |
PE20130602A1 (es) | 2010-08-12 | 2013-05-25 | Boehringer Ingelheim Int | Derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d)pirimidin-4-onas y su uso como inhibidores de pde9a |
US8541391B2 (en) | 2010-10-28 | 2013-09-24 | Viropharma Incorporated | Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H-benzimidazole |
US8501484B2 (en) | 2011-03-14 | 2013-08-06 | Los Alamos National Security, Llc | Preparation of cerium halide solvate complexes |
MX2011004759A (es) | 2011-05-04 | 2012-11-21 | Senosiain S A De C V Lab | Nuevas formas solidas de antibioticos. |
PL2710005T3 (pl) | 2011-05-17 | 2017-07-31 | Principia Biopharma Inc. | Inhibitory kinazy tyrozynowej |
WO2013012959A1 (en) | 2011-07-18 | 2013-01-24 | Tokai Pharmaceuticals, Inc. | Novel compositions and methods for treating prostate cancer |
SI2751109T1 (sl) | 2011-09-02 | 2017-03-31 | Incyte Holdings Corporation | Heterociklilamini kot inhibitorji pi3k |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
AU2013208323B2 (en) | 2012-01-13 | 2017-07-06 | Xspray Microparticles Ab | A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component. |
US8501724B1 (en) | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
JP5514256B2 (ja) | 2012-05-18 | 2014-06-04 | 株式会社東芝 | 磁気記憶素子及びその製造方法 |
NZ702548A (en) * | 2012-06-04 | 2015-11-27 | Pharmacyclics Llc | Crystalline forms of a bruton’s tyrosine kinase inhibitor |
US20160045503A1 (en) | 2012-06-18 | 2016-02-18 | Principia Biopharma Inc. | Formulations containing reversible covalent compounds |
WO2014004707A1 (en) | 2012-06-29 | 2014-01-03 | Principia Biopharma Inc. | Formulations comprising ibrutinib |
JP6575950B2 (ja) | 2012-07-24 | 2019-09-18 | ファーマサイクリックス エルエルシー | Bruton型チロシンキナーゼ(Btk)阻害剤に対する耐性を伴う変異 |
CN103121999A (zh) | 2012-08-29 | 2013-05-29 | 苏州迪飞医药科技有限公司 | 一种酪氨酸激酶抑制剂pci-32765的合成方法 |
MX2015006168A (es) | 2012-11-15 | 2015-08-10 | Pharmacyclics Inc | Compuestos de pirrolopirimidina como inhibidores de quinasas. |
WO2014168975A1 (en) | 2013-04-08 | 2014-10-16 | Pharmacyclics, Inc. | Ibrutinib combination therapy |
WO2014179528A2 (en) * | 2013-05-01 | 2014-11-06 | Brown Dennis M | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted naphthalimides such as amonafide for the treatment of immunological, metabolic, infectious, and benign or neoplastic hyperproliferative disease conditions |
DK3003309T3 (da) | 2013-05-30 | 2020-12-14 | Infinity Pharmaceuticals Inc | Behandling af cancer med PI3-kinase-isoform modulatorer |
JP6800750B2 (ja) | 2013-08-02 | 2020-12-16 | ファーマサイクリックス エルエルシー | 固形腫瘍の処置方法 |
CA2920534A1 (en) | 2013-08-12 | 2015-02-19 | Pharmacyclics Llc | Methods for the treatment of her2 amplified cancer |
US10253244B2 (en) | 2013-09-04 | 2019-04-09 | Halliburton Energy Services, Inc. | Scale-inhibiting cocrystals for treatment of a subterranean formation |
CA2922398C (en) | 2013-09-12 | 2023-08-29 | Dana-Farber Cancer Institute, Inc. | Methods for evaluating and treating waldenstrom's macroglobulinemia |
CN104447701B (zh) | 2013-09-17 | 2019-03-22 | 广东东阳光药业有限公司 | 吡唑类衍生物及其用途 |
BR112016009200A8 (pt) | 2013-10-25 | 2020-03-24 | Pharmacyclics Llc | uso de um inibidor de btk e um inibidor imune do ponto de verificação |
US9795604B2 (en) | 2013-10-25 | 2017-10-24 | Pharmacyclics Llc | Methods of treating and preventing graft versus host disease |
WO2015071432A1 (en) | 2013-11-14 | 2015-05-21 | Sandoz Ag | Pharmaceutical compositions of ibrutinib |
CN103694241A (zh) | 2013-11-27 | 2014-04-02 | 苏州晶云药物科技有限公司 | Pci-32765的新晶型a及其制备方法 |
CA3210338A1 (en) | 2013-12-02 | 2015-06-11 | Pharmacyclics Llc | Methods of treating and preventing alloantibody driven chronic graft versus host disease |
CA2929918C (en) | 2013-12-05 | 2018-01-23 | F. Hoffmann-La Roche Ag | Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality |
US20160310417A1 (en) | 2013-12-20 | 2016-10-27 | Emory University | Formulations and Methods For Targeted Ocular Delivery of Therapeutic Agents |
CN105949198A (zh) | 2014-01-29 | 2016-09-21 | 苏州晶云药物科技有限公司 | 依鲁替尼的新晶型及其制备方法 |
WO2015120110A2 (en) | 2014-02-07 | 2015-08-13 | Auspex Pharmaceuticals, Inc. | Novel pharmaceutical formulations |
US20150231077A1 (en) | 2014-02-17 | 2015-08-20 | The Cleveland Clinic Foundation | Amine passivated nanoparticles for cancer treatment and imaging |
WO2015127261A1 (en) | 2014-02-21 | 2015-08-27 | Pharmacyclics, Inc. | Biomarkers for predicting response of dlbcl to treatment with ibrutinib |
US20150267752A1 (en) | 2014-03-19 | 2015-09-24 | Roller Bearing Company Of America, Inc. | Bearing outer race having a radially inwardly biased seal |
US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
MX2016012419A (es) | 2014-03-27 | 2016-11-30 | Perrigo Api Ltd | Formas solidas de ibrutinib y procesos para la produccion de las mismas. |
WO2015149056A1 (en) | 2014-03-28 | 2015-10-01 | Board Of Regents, The University Of Texas System | Inhibition of bruton's tyrosine kinase (btk) in the lung to treat severe lung inflammation and lung injury |
CN105085529A (zh) | 2014-05-15 | 2015-11-25 | 广东东阳光药业有限公司 | 依鲁替尼新晶型及其制备方法 |
US9127069B1 (en) | 2014-06-11 | 2015-09-08 | Antecip Bioventures LLC | Compositions comprising rank/rankl antagonists and related compounds for treating pain |
US20150110871A1 (en) | 2014-06-02 | 2015-04-23 | David Wong | Gastric retentive tablet compositions |
WO2016007617A2 (en) | 2014-07-09 | 2016-01-14 | Novotec Consulting, Llc. | Pharmaceutical compounding kit |
PT107846B (pt) | 2014-08-01 | 2019-03-22 | Hovione Farm S A | Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada |
WO2016020697A1 (en) | 2014-08-06 | 2016-02-11 | Cipla Limited | Pharmaceutical compositions of polymeric nanoparticles |
JP2017523206A (ja) | 2014-08-07 | 2017-08-17 | ファーマサイクリックス エルエルシー | ブルトン型チロシンキナーゼ阻害剤の新規製剤 |
WO2016025720A1 (en) | 2014-08-14 | 2016-02-18 | Assia Chemical Industries Ltd. | Solid state forms of ibrutinib |
WO2016050422A1 (en) | 2014-10-01 | 2016-04-07 | Ratiopharm Gmbh | Acid addition salt of ibrutinib |
CN104523695A (zh) | 2014-11-12 | 2015-04-22 | 广东东阳光药业有限公司 | 一种治疗过度增生性疾病的药物组合物 |
CN105640961A (zh) | 2014-11-18 | 2016-06-08 | 山东瑞禾医药科技有限公司 | 一种含依鲁替尼的药物组合物 |
WO2016079216A1 (en) | 2014-11-20 | 2016-05-26 | Sandoz Ag | Physical forms of ibrutinib, a bruton's kinase inhibitor |
US20150224060A1 (en) | 2015-01-03 | 2015-08-13 | David Wong | Gastric retentive tablet compositions |
CZ201584A3 (cs) | 2015-02-09 | 2016-08-17 | Zentiva, K.S. | Sůl Ibrutinib sulfátu |
BR122023020985A2 (pt) | 2015-03-03 | 2023-12-26 | Pharmacyclics Llc | Formulação de comprimido sólido de um inibidor de tirosina quinase de bruton |
RU2017133663A (ru) | 2015-03-03 | 2019-04-03 | Др. Редди'С Лабораторис Лимитед | П0лиморфы ибрутиниба |
MA41827A (fr) | 2015-03-27 | 2018-01-30 | Pharmacyclics Llc | Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton |
MA41828A (fr) | 2015-03-27 | 2018-01-30 | Pharmacyclics Llc | Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton |
CN107873029B (zh) | 2015-04-02 | 2020-09-01 | 拉蒂奥法姆有限责任公司 | 依鲁替尼与羧酸的共晶体 |
MA41901A (fr) | 2015-04-06 | 2021-04-14 | Janssen Pharmaceutica Nv | Compositions contenant de l'ibrutinib |
CN105294696A (zh) | 2015-11-19 | 2016-02-03 | 上海创诺医药集团有限公司 | 依鲁替尼新晶型及其制备方法 |
CN105440040B (zh) | 2015-12-23 | 2018-03-13 | 浙江京新药业股份有限公司 | 依鲁替尼的纯化方法 |
CN114681462A (zh) | 2016-01-19 | 2022-07-01 | 詹森药业有限公司 | 包含btk抑制剂的配制品/组合物 |
AU2017208472B2 (en) | 2016-01-19 | 2022-09-01 | Janssen Pharmaceutica Nv | Formulations/compositions comprising a BTK inhibitor |
CN105646498A (zh) | 2016-03-01 | 2016-06-08 | 孙霖 | 依鲁替尼晶型f及制备方法 |
CN105646484A (zh) | 2016-03-01 | 2016-06-08 | 孙霖 | 晶型b及制备方法 |
CN105646499A (zh) | 2016-03-01 | 2016-06-08 | 孙霖 | 依鲁替尼晶型g及制备方法 |
CN106619643A (zh) | 2016-11-11 | 2017-05-10 | 上海雅本化学有限公司 | 一种含依鲁替尼的药物组合物 |
-
2013
- 2013-06-03 NZ NZ702548A patent/NZ702548A/en unknown
- 2013-06-03 JO JOP/2013/0168A patent/JO3754B1/ar active
- 2013-06-03 SG SG10202101389TA patent/SG10202101389TA/en unknown
- 2013-06-03 PE PE2014002374A patent/PE20150174A1/es not_active Application Discontinuation
- 2013-06-03 TW TW107101564A patent/TWI662963B/zh active
- 2013-06-03 KR KR1020197010159A patent/KR20190040370A/ko not_active Application Discontinuation
- 2013-06-03 US US14/405,317 patent/US9540382B2/en active Active
- 2013-06-03 NZ NZ713828A patent/NZ713828A/en unknown
- 2013-06-03 PE PE2019000040A patent/PE20190390A1/es unknown
- 2013-06-03 AU AU2013271918A patent/AU2013271918C1/en active Active
- 2013-06-03 KR KR1020237041085A patent/KR20230170108A/ko not_active Application Discontinuation
- 2013-06-03 MA MA41654A patent/MA41654B2/fr unknown
- 2013-06-03 TW TW102119583A patent/TWI653041B/zh active
- 2013-06-03 US US13/908,949 patent/US9296753B2/en active Active
- 2013-06-03 MY MYPI2014003370A patent/MY187999A/en unknown
- 2013-06-03 NZ NZ731932A patent/NZ731932A/en unknown
- 2013-06-03 WO PCT/US2013/043888 patent/WO2013184572A1/en active Application Filing
- 2013-06-03 TW TW107137018A patent/TWI662964B/zh active
- 2013-06-03 NZ NZ737725A patent/NZ737725A/en unknown
- 2013-06-03 KR KR1020207003793A patent/KR20200017549A/ko active Application Filing
- 2013-06-03 MX MX2014014848A patent/MX348290B/es active IP Right Grant
- 2013-06-03 CN CN201380041392.XA patent/CN104736178A/zh active Pending
- 2013-06-03 BR BR112014030424A patent/BR112014030424A8/pt not_active Application Discontinuation
- 2013-06-03 CA CA3218491A patent/CA3218491A1/en active Pending
- 2013-06-03 MY MYPI2018000375A patent/MY194911A/en unknown
- 2013-06-03 CN CN201910730441.XA patent/CN110354132A/zh active Pending
- 2013-06-03 SG SG11201408067YA patent/SG11201408067YA/en unknown
- 2013-06-03 KR KR1020177021511A patent/KR20170091785A/ko active Application Filing
- 2013-06-03 KR KR1020147036843A patent/KR20150015021A/ko not_active Application Discontinuation
- 2013-06-03 CA CA3015208A patent/CA3015208C/en active Active
- 2013-06-03 CA CA2991994A patent/CA2991994C/en active Active
- 2013-06-03 EA EA201492082A patent/EA201492082A1/ru unknown
- 2013-06-03 JP JP2015516091A patent/JP6236071B2/ja active Active
- 2013-06-03 KR KR1020217007940A patent/KR20210033067A/ko not_active Application Discontinuation
- 2013-06-03 UA UAA201700877A patent/UA126959C2/uk unknown
- 2013-06-03 MA MA37711A patent/MA37711A1/fr unknown
- 2013-06-03 KR KR1020227021197A patent/KR20220093389A/ko not_active IP Right Cessation
- 2013-06-03 CA CA2875986A patent/CA2875986C/en active Active
- 2013-06-03 EP EP13799982.7A patent/EP2854859A4/en active Pending
- 2013-06-03 UA UAA201414091A patent/UA114421C2/uk unknown
- 2013-06-04 UY UY0001039740A patent/UY39740A/es not_active Application Discontinuation
- 2013-06-04 AR ARP130101974A patent/AR092844A1/es unknown
- 2013-06-04 UY UY0001034848A patent/UY34848A/es not_active Application Discontinuation
-
2014
- 2014-07-23 US US14/339,363 patent/US20140336203A1/en not_active Abandoned
- 2014-11-25 TN TN2014000492A patent/TN2014000492A1/fr unknown
- 2014-11-25 IL IL235894A patent/IL235894B/en active IP Right Grant
- 2014-11-27 DO DO2014000274A patent/DOP2014000274A/es unknown
- 2014-12-01 PH PH12014502681A patent/PH12014502681A1/en unknown
- 2014-12-03 CL CL2014003306A patent/CL2014003306A1/es unknown
- 2014-12-04 GT GT201400281A patent/GT201400281A/es unknown
- 2014-12-04 CR CR20140558A patent/CR20140558A/es unknown
- 2014-12-04 MX MX2021012478A patent/MX2021012478A/es unknown
- 2014-12-16 CO CO14276324A patent/CO7240408A2/es unknown
- 2014-12-24 EC ECIEPI201433163A patent/ECSP14033163A/es unknown
-
2015
- 2015-09-25 HK HK15109505.2A patent/HK1208803A1/xx unknown
-
2016
- 2016-10-28 AU AU2016250445A patent/AU2016250445B2/en active Active
- 2016-12-21 US US15/386,118 patent/US9713617B2/en active Active
-
2017
- 2017-02-13 CL CL2017000371A patent/CL2017000371A1/es unknown
- 2017-04-26 US US15/497,896 patent/US9725455B1/en active Active
- 2017-06-22 DO DO2017000152A patent/DOP2017000152A/es unknown
- 2017-07-10 US US15/645,319 patent/US20170305919A1/en not_active Abandoned
- 2017-08-07 US US15/670,614 patent/US9828383B1/en active Active
- 2017-08-17 JP JP2017157676A patent/JP2018012710A/ja active Pending
- 2017-09-27 IL IL254739A patent/IL254739A0/en unknown
- 2017-10-26 JP JP2017207591A patent/JP2018048182A/ja active Pending
- 2017-12-29 CL CL2017003496A patent/CL2017003496A1/es unknown
-
2018
- 2018-02-02 US US15/887,712 patent/US20180170940A1/en not_active Abandoned
- 2018-02-02 US US15/887,744 patent/US20180155352A1/en not_active Abandoned
- 2018-02-20 US US15/900,660 patent/US10106548B2/en active Active
- 2018-02-21 US US15/901,118 patent/US10065968B2/en active Active
- 2018-07-13 US US16/035,449 patent/US10266540B2/en active Active
- 2018-07-16 US US16/036,207 patent/US20180319805A1/en not_active Abandoned
- 2018-07-16 US US16/036,258 patent/US10125140B1/en active Active
- 2018-07-31 AU AU2018211201A patent/AU2018211201B2/en active Active
- 2018-07-31 AU AU2018211216A patent/AU2018211216B2/en active Active
- 2018-08-23 US US16/111,014 patent/US10294232B2/en active Active
- 2018-08-23 US US16/110,999 patent/US10294231B2/en active Active
- 2018-08-23 US US16/110,969 patent/US20180362534A1/en not_active Abandoned
-
2019
- 2019-03-06 EC ECSENADI201915794A patent/ECSP19015794A/es unknown
- 2019-04-24 US US16/393,797 patent/US20190248799A1/en not_active Abandoned
- 2019-04-24 US US16/393,775 patent/US20190248798A1/en not_active Abandoned
- 2019-07-16 JP JP2019131481A patent/JP6937086B6/ja active Active
- 2019-09-06 JP JP2019163455A patent/JP2020015744A/ja active Pending
-
2020
- 2020-01-02 PH PH12020500028A patent/PH12020500028A1/en unknown
- 2020-01-15 US US16/744,007 patent/US20200148691A1/en not_active Abandoned
- 2020-02-14 AR ARP200100425A patent/AR118108A2/es unknown
- 2020-03-19 US US16/824,630 patent/US20200231595A1/en not_active Abandoned
- 2020-04-01 US US16/837,665 patent/US10752634B2/en active Active
- 2020-09-09 JO JOP/2020/0222A patent/JOP20200222A1/ar unknown
- 2020-09-24 AU AU2020239751A patent/AU2020239751B2/en active Active
- 2020-10-08 US US17/066,192 patent/US20210032258A1/en not_active Abandoned
- 2020-11-18 US US16/951,796 patent/US10961251B1/en active Active
-
2021
- 2021-04-18 IL IL282367A patent/IL282367A/en unknown
- 2021-05-24 US US17/328,644 patent/US20220112196A1/en not_active Abandoned
- 2021-07-22 ZA ZA2021/05174A patent/ZA202105174B/en unknown
- 2021-07-22 ZA ZA2021/05175A patent/ZA202105175B/en unknown
- 2021-07-26 JP JP2021121857A patent/JP2021183617A/ja active Pending
- 2021-08-24 JP JP2021136489A patent/JP2021193095A/ja active Pending
-
2022
- 2022-05-06 DO DO2022000096A patent/DOP2022000096A/es unknown
-
2023
- 2023-01-27 AU AU2023200435A patent/AU2023200435A1/en active Pending
- 2023-03-01 ZA ZA2023/03227A patent/ZA202303227B/en unknown
- 2023-07-13 JP JP2023115449A patent/JP2023162162A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2022000096A (es) | Formas cristalinas de un inhibidor de tirosina quinasa de bruton | |
MX2017001671A (es) | Formulaciones novedosas de un inhibidor de la tirosina cinasa de bruton. | |
MX2021015368A (es) | Composiciones farmaceuticas de un inhibidor de tirosina cinasa de bruton. | |
MX2017012411A (es) | Co-cristales de un inhibidor de tirosina cinasa de bruton. | |
CL2012000917A1 (es) | Compuestos derivados de pirazolo [3,4-d] pirimidina, inhibidores btk; y uso en el tratamiento del cancer, enfermedades autoinmune, mastocitosis,osteoporosis,entre otras. | |
EA201591656A1 (ru) | Комбинированная терапия с ибрутинибом | |
NI201500067A (es) | Compuestos de pirrolopirimidina como inhibidores de quinasa | |
CL2008003575A1 (es) | Compuestos derivados de 1,5-dihidropirazolo[3,4-d]piridin-4-ona, inhibidores de pde9a; composicion farmaceutica que los comprende; y su uso en el tratamiento y prevencion del alzheimer, parkinson, esclerosis multiple, demencia vascular, esquizofrenia con demencia, entre otras. | |
EA201790995A1 (ru) | ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ | |
BR112015021995A2 (pt) | combinações de inibidores de tirosina quinase de bruton e inibidores de cyp3a4 | |
ECSP088440A (es) | Imidazopirazinas como inhibidores de proteinquinasa | |
ECSP088345A (es) | Nuevas pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina | |
CL2011002955A1 (es) | Compuestos derivados de 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octanonitrilo o heptanonitrilo o sus sales, como inhibidores de jak; procedimiento de preparacion; composicion farmaceutica que los comprende; utiles para el tratamiento de trastornos autoinmunes, cancer, entre otras enfermedades. | |
MX2017012430A (es) | Formas solvatadas de un inhibidor de tirosina quinasa de bruton. | |
SG10201906517VA (en) | Synthesis of a bruton's tyrosine kinase inhibitor | |
BR112014001665A2 (pt) | compostos de 2,3-di-hidroimidazo[1,2-c]pirimidin-5(1h)-ona utilizados como inibidores de lp-plaz | |
ECSP10010389A (es) | Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteina quinasa | |
AR103832A1 (es) | Formulaciones farmacéuticas de un inhibidor de tirosina quinasa de bruton |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RDES | Application refused |
Effective date: 20230414 |